This Alum Visited China at the Beginning of the Pandemic

What he learned may have helped save lives in the U.S.

Author | Katie Whitney

Do you remember what you knew about COVID-19 in January of 2020? Probably not much.

The same was true for H. Clifford Lane (M.D. 1976, Residency 1979), who works at the National Institutes of Health (NIH) as deputy director for clinical research and special projects at the National Institute of Allergies and Infectious Diseases. He had seen news articles and research papers about this disease in China that looked like a new kind of pneumonia.

But he first began to suspect this was a bigger deal when he saw a TV news story about new hospitals being built in Wuhan. Hospitals that were going to have a huge number of beds.

In February 2020, he became one of two U.S. representatives to visit China at the behest of the World Health Organization (WHO). He was on his way to Japan when he got the invitation from WHO. Lane called his boss, Anthony Fauci, M.D., who told Lane he ought to accept. Along with the delegates drawn from eight countries, it would be Lane's job to figure out what was going on and what the rest of the world could do to mitigate impending disaster.

Lane spent 24 hours in Japan prepping for his trip to China. Although there were relatively few COVID-19 cases in Japan at the time, Lane had more trouble acquiring masks and hand sanitizer than he did getting a visa. As for the sanitizer, the familiar alcohol-based stuff was totally unavailable, and all he could find was "basically bleach." Masks were even more difficult to obtain. He ended up being the only person on his flight to Beijing without one.

When he arrived, Beijing looked deserted. His flight was the only one arriving at the airport, and the streets of the city were eerily empty.

Lane spent his time in China visiting hospitals, markets, community centers, clinics, and other places in different cities. "I think what stuck with me the most was seeing how incredibly organized, orchestrated, and single-messaged the entire population was. They were at war with COVID-19," he says. Lane acknowledged the Chinese government's control over the message, but he believes the information he got was accurate. "You visit hospitals, you can tell how many beds are full. There are things you can't hide."

Lane also noticed that the government frequently put out treatment guidelines as they learned more about the disease. He says the initial mortality rate in Wuhan was 7-10%, but it came down very quickly, thanks to the quick communication of up-to-date therapeutic strategies with clinicians. Lane brought that idea back to the U.S. and put together a panel of experts to create NIH treatment guidelines, which have since been updated dozens of times as new information became available.

Lane says the COVID-19 vaccines give him hope. "Many people would say they are an unprecedented success in terms of speed, efficacy, and safety. This is really quite remarkable," he says. "There is a way out."

But he worries about the lack of vaccination on a global scale. "As long as there is a substantial population susceptible to this virus, the virus is going to continue to change in a way that makes it, for lack of a better word, stronger. It's not done by the virus having a will. It's just done by the principles of biology and evolution."

Lane, who also received his undergraduate degree from U-M, is currently working on research around treatment options — specifically monoclonal antibodies and immunoglobulin. He says both are promising.

As for Fauci, Lane has worked for 42 years with the physician who has become a household name. "Dr. Fauci is the same now as he was when I first met him — dedicated, hardworking … keeping his eye on the goal, not easily distracted," says Lane. "Now more than ever, it's been important for him and those around him to maintain that focus."


More Articles About: pandemic Covid-19 alum Alumni infectious disease Anthony Fauci National Institutes of Health China
Featured News & Stories lungs beating pink and orange and yellow and white circles floating around
Health Lab
Protein found in rheumatic diseases causes inflammation in COVID-19 patients
Research on the inflammatory mediator called sCD13 has identified this molecule and its receptors as new targets for treatment of autoimmune rheumatic diseases. The data suggests that sCD13 may also be of great importance in severe complications of COVID-19.
Medical student Jessie Dalman assisting her father, Ronald Dalman (M.D. 1984), in the OR. Both are wearing surgical scrubs and masks.
Medicine at Michigan
Class Notes for spring 2025
Updates from graduates of the U-M Medical School.
Medicine at Michigan
Obituary — Roger F. Meyer, M.D.
Remembering Roger F. Meyer, M.D. (Residency 1971).
Michigan Medicine Presents... on dark blue background with two lights shining on the words
Michigan Medicine Presents
Episode 1: The Science of Bipolar Disorder
Bipolar disorder is more than just mood swings. It’s a journey marked by intense highs of mania and debilitating lows of depression. But within this condition exist millions of people who live unique lives. Today, we're going to talk to three clinical and research experts from the Heinz C. Prechter Bipolar Research Program at Michigan Medicine to learn more about the science of bipolar disorder—diagnostics, genetics, and decision-making. We'll be hearing from Dr. Melvin McInnis, director of the Prechter Program, Dr. Paul Jenkins, associate professor of pharmacology and associate director of the Prechter Program, and Dr. Chandra Sripada, professor of psychiatry and philosophy.
woman pregnant sitting holding tea and glasses on brown hair
Health Lab
Revolutionizing prenatal care: new guidelines to transform 100-year model
The American College of Obstetricians and Gynecologists, which collaborated with Michigan Medicine teams, is recommending significant changes to the way prenatal care is delivered in the United States, according to newly released clinical guidance.
water droplet with money in it
Health Lab
Investing in COVID-19 vaccination more than paid off for U.S.
The money spent to develop, test, buy and administer the first COVID-19 vaccine was more than made up for by prevented medical care and lost productivity.